跳至主要内容
临床试验/NCT00739297
NCT00739297已完成1 期

A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Bronchodilatory Effect of MK0476 in Patients With Chronic Asthma

Organon and Co0 个研究点目标入组 68 人开始时间: 2008年7月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
68
主要终点
Change From Baseline in FEV1 Over 4 Hours

研究概览

简要总结

This study will test the safety and effectiveness of a range of doses of MK0476 (montelukast) compared to placebo on improved lung function in patients with chronic asthma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
15 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • A person is 15 to 65 years of age. A person has had chronic asthma for at least one year

排除标准

  • A person is a smoker or has smoked more that a pack a day for more than 10 years before stopping
  • A person has other lung disorders such as COPD (chronic obstructive pulmonary disorder)

结局指标

主要结局

Change From Baseline in FEV1 Over 4 Hours

时间窗: 0 (=baseline) to 4 hours after treatment with montelukast

FEV1 measurements taken at 0 (=baseline), 10, 20, 30, 45, 60, 120, 180 and 240 minutes contributed to the average change from baseline over 4 hours. The number of minutes between consecutive measurements was used as weighting factor. The time-weighted average change was standardized by dividing by the time associated with the last measurement.

次要结局

  • Change From Baseline in FEV1 Over 90 Minutes After Albuterol/Placebo Administration(4 hours (equals time point at which albuterol or albuterol placebo is administered) to 5.5 hours after treatment with montelukast)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验